Barrett's esophagus. *Clin Gastroenterol Hepatol*. 2006;4:566-72.

4. Sikkema M, Looman CW, Steyerberg EW, Kerkhof M, Kastelein F, van Dekken H, et al. Predictors for neoplastic progression in patients with Barrett's esophagus: a prospective cohort study. *Am J Gastroenterol*. 2011;106:1231-8.
5. Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large, population-based study. *J Natl Cancer Inst*. 2011;103:1049-57.
6. Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. *N Engl J Med*. 2009;360:2277-88.

doi:10.1016/j.jtcvs.2011.12.055

Reply to the Editor:

I am in agreement with Drs Korst and Lee that there may be certain populations with nondysplastic Barrett's esophagus (BE) who may be at increased risk for esophageal cancer. There are currently no compelling data, however, to recommend any intervention beyond repeated surveillance endoscopy in patients with BE. The American Gastroenterological Association based its recommendation for surveillance on an estimated rate of progression of disease to high-grade dysplasia or adenocarcinoma of 0.5%. Recent large, population-based studies suggest that this risk estimate is actually too high. Hvid-Jensen and colleagues¹ reported in the *New England Journal of Medicine* in October 2011 an annual risk of progression to adenocarcinoma in patients with BE of 0.12%. This finding was based on analysis of a comprehensive database that included the entire population of Denmark. In a similar study of the entire population of Northern Ireland, Bhat and colleagues² reported a nearly identical absolute annual risk of 0.13%.

Current data indicate that the risk to the patient of malignant transformation from BE is even lower than previously thought, suggesting caution with invasive strategies that may in fact be over-treatment. There may be a role for radiofrequency ablation in selected—and currently undefined—subgroups of patients with nondysplastic BE.

Given the overall low cancer risk, the bar is set very high to prove cost-effectiveness, reduction in cancer progression, or reduction in mortality. I believe that radiofrequency ablation for nondysplastic BE is therefore difficult to justify, outside of a well-reasoned clinical trial.

Nirmal K. Veeramachaneni, MD
Division of Cardiothoracic Surgery
University of North Carolina—Chapel Hill
Chapel Hill, NC

References

1. Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. *N Engl J Med*. 2011;365:1375-83.
2. Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. *J Natl Cancer Inst*. 2011;103:1049-57.

doi:10.1016/j.jtcvs.2012.01.023

VENOVENOUS EXTRACORPOREAL MEMBRANE OXYGENATION IN ACUTE RESPIRATORY FAILURE: DO WE NEED A NEW CONFIGURATION?

To the Editor:

We read with great interest the article by Bonacchi and colleagues¹ in a recent issue of *The Journal of Thoracic and Cardiovascular Surgery*. Bonacchi and colleagues¹ presented their experience with the use of venovenous extracorporeal membrane oxygenation (ECMO) in 30 patients with severe acute respiratory failure and described their experience with the use of a customized arterial cannula to reduce the blood recirculation fraction (BRF) when high ECMO flows are needed to improve systemic oxygenation. In their "χ" configuration, a traditional inflow cannula is modified by making a 60° angle in its distal third to allow tip orientation toward the tricuspid valve. In their series, Bonacchi and colleagues¹ reported significant improvements in

oxygenation indices and a reduction of more than 20% in the BRF. Importantly, the study showed that the modified cannula can be used safely without mechanical complications.

The problem of recirculation with a double-lumen catheter for venovenous ECMO has been well studied in both animal and human models.²⁻⁴ In patients with acute respiratory failure who require high ECMO flow support, a low BRF is key to ensure adequate systemic oxygen delivery. The study by Bonacchi and colleagues¹ addresses this important issue and demonstrates that a low BRF is associated with successful venovenous ECMO in patients with respiratory distress. Although we recognize the efforts of Bonacchi and colleagues¹ to develop a new strategy to overcome the problem of BRF when high ECMO flows are needed, we would like to point out several important points that they failed to include in their report. First, a bicaval dual-lumen catheter that is already available in the United States (Avalon Elite; Avalon Laboratories LLC, Rancho Dominguez, Calif) can be safely and successfully used to provide adequate venovenous ECMO support in patients with acute respiratory failure.⁵ Second, the use of this dual-lumen Avalon Elite cannula offers the advantage of single-site cannulation, eliminates the need to use multiple catheters, and avoids the use femoral vascular access.⁵ Third, studies have shown that the use of the dual-lumen Avalon Elite cannula results in a very small BRF (as low as 2%).⁶ Finally, placement of the dual-lumen Avalon Elite cannula can be successfully achieved with fluoroscopic and a transthoracic echocardiographic guidance and does not require an invasive transesophageal approach.⁷

Although we applaud the efforts of Bonacchi and colleagues¹ and recognize the value of their technique in overcoming the problem of BRF, we believe that the use of the currently